Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1044 clinical trials
featured
RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

  • 200 views
  • 08 Nov, 2020
  • 1 location
featured
ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

  • 254 views
  • 08 Nov, 2020
  • 1 location
featured
INDUCE-3 - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

People with Head and Neck Squamous Cell Carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.  

carcinoma
squamous cell carcinoma
  • 25 views
  • 01 May, 2020
  • 1 location
featured
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • 612 views
  • 08 Nov, 2020
  • 1 location
featured
RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

  • 746 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 128 views
  • 14 Dec, 2020
  • 4 locations
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC). This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 …

carcinoma of oropharynx
cancer
gsk3359609
oropharyngeal
human papillomavirus
  • 6 views
  • 25 Feb, 2021
  • 184 locations
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase …

carcinoma of oropharynx
gsk3359609
carboplatin
oropharyngeal
measurable disease
  • 0 views
  • 25 Feb, 2021
  • 74 locations
Trial of E10A in Head and Neck Cancer

randomized phase II trial to explore the safety and effectiveness of E10A combined with chemotherapy in the treatment of patients with head and neck cancer.

paclitaxel
metastasis
angiogenesis inhibitor
cancer
endostatin
  • 7 views
  • 07 Nov, 2020
  • 1 location